FDA Awards $21.6M for Analytical Instruments to BioMérieux Inc. Under Existing IDIQ

Contract Overview

Contract Amount: $21,662 ($21.7K)

Contractor: Biomerieux Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2026-04-06

End Date: 2026-07-28

Contract Duration: 113 days

Daily Burn Rate: $192/day

Competition Type: NOT COMPETED

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: DELIVERY/TASK ORDER FOR FDA/NYHAFL BIOMERIEUX IDIQ CONTRACT, THREE DELIVERIES.

Place of Performance

Location: IRVINE, ORANGE County, CALIFORNIA, 92612

State: California Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $21,662.16 to BIOMERIEUX INC for work described as: DELIVERY/TASK ORDER FOR FDA/NYHAFL BIOMERIEUX IDIQ CONTRACT, THREE DELIVERIES. Key points: 1. Contract awarded to BioMérieux Inc. for analytical laboratory instruments. 2. The contract is a delivery order under an existing IDIQ. 3. The award is for a firm fixed price contract. 4. The contract duration is 113 days. 5. The contract was not competed.

Value Assessment

Rating: questionable

The contract value of $21.6M for a 113-day delivery order seems high. Without a per-unit cost or comparison to similar instruments, it's difficult to assess value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was not competed, indicating a sole-source award. This limits price discovery and potentially leads to higher costs for taxpayers.

Taxpayer Impact: The lack of competition may result in the government paying more than necessary for these analytical instruments.

Public Impact

Ensures FDA has necessary analytical instruments for its operations. Potential for increased costs due to non-competitive award. Limited transparency on pricing and justification for sole-source award.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition
High value for short duration
Potential for overpayment

Positive Signals

Supports critical FDA functions
Utilizes existing IDIQ contract

Sector Analysis

This award falls under the Analytical Laboratory Instrument Manufacturing sector. Spending in this sector can vary widely based on agency needs and technological advancements. The $21.6M for a short-term delivery order is notable.

Small Business Impact

The contract was awarded to BioMérieux Inc., a large business. There is no indication of small business participation in this specific delivery order.

Oversight & Accountability

The non-competitive nature of this award warrants further oversight to ensure the price is fair and reasonable and that future procurements are competed where possible.

Related Government Programs

Analytical Laboratory Instrument Manufacturing
Department of Health and Human Services Contracting
Food and Drug Administration Programs

Risk Flags

Lack of competition
Potential for inflated pricing
Limited transparency
High value for short duration

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $21,662.16 to BIOMERIEUX INC. DELIVERY/TASK ORDER FOR FDA/NYHAFL BIOMERIEUX IDIQ CONTRACT, THREE DELIVERIES.

Who is the contractor on this award?

The obligated recipient is BIOMERIEUX INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Food and Drug Administration).

What is the total obligated amount?

The obligated amount is $21,662.16.

What is the period of performance?

Start: 2026-04-06. End: 2026-07-28.

What is the justification for awarding this delivery order on a sole-source basis, and what steps were taken to ensure a fair and reasonable price?

The justification for a sole-source award typically involves unique capabilities or circumstances. The government should have conducted a price analysis, comparing proposed costs to historical prices, commercial prices, or independent government estimates to ensure the price paid is fair and reasonable. Documentation of this analysis is crucial for accountability.

What is the per-unit cost of the analytical instruments being procured, and how does it compare to market benchmarks?

Without specific details on the number of units or the exact type of instruments, a precise per-unit cost cannot be determined. However, given the $21.6M value for a 113-day delivery, the per-unit cost is likely substantial. A comparison to similar instruments from other manufacturers or previous government purchases would be necessary to assess if the price is competitive.

What is the long-term strategy for procuring these analytical instruments, and will future requirements be competed?

The long-term strategy is unclear from this data. If this is a recurring need, the FDA should explore options for full and open competition in future solicitations to leverage market forces and achieve better pricing. Relying on sole-source awards for essential equipment can lead to sustained higher costs and reduced innovation.

Industry Classification

NAICS: Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Analytical Laboratory Instrument Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 100 RODOLPHE ST, DURHAM, NC, 27712

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $21,662

Exercised Options: $21,662

Current Obligation: $21,662

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 75F40121D00021

IDV Type: IDC

Timeline